MobiDrop specializes in developing microfluidic technologies aimed at enhancing life sciences and precision medicine. The company creates advanced instruments, comprehensive assays, and user-friendly software designed for digital droplet PCR (ddPCR) and single-cell multi-omic platforms. MobiDrop is dedicated to innovating molecular diagnostics and life science research by improving the quality of diagnosis and testing. Its product portfolio includes integrated machine platforms, microfluidic detection chips, and supporting reagents, which find applications in molecular diagnostics, cancer screening, and drug research and development. Through these offerings, MobiDrop contributes significantly to the advancement of life science research and in vitro diagnostics.
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields.
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.
Boyue Bio focuses on the development of biomedical raw materials and integrated solutions. The company's four product lines include Bioactive Materials, Nanometer Microspheres, Chromatographic Products, and Integrated Solutions. Boyue Bio seeks to be a major provider of total solutions and core raw materials for the biomedical industry.
Elixir Clinical Research is a technology-driven contract research organization (CRO) that specializes in providing comprehensive clinical research services. The company aims to facilitate the rapid launch of new drugs by offering a range of services, including bioequivalence studies, Phase I-IV clinical trials, real-world research, and final application registration. Elixir also supports clients in designing research programs, developing medical strategies, managing regulatory processes, overseeing clinical centers, and handling data management and biostatistics. By delivering qualified and effective clinical research solutions, Elixir assists pharmaceutical companies in navigating the complexities of drug development and regulatory approval.
Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
Medilink Therapeutics
Series B in 2022
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
Genepoint Biological Technology (China) Co., Ltd. is a Shanghai-based company that specializes in the manufacturing of devices for cryogenic biomaterial storage and handling. Its product line includes Automated Cryo-Bio Storage systems, Plugged Hybrid Cryo-Storage units, LIN Vapor Freezers, and hoists designed for freezer operations. These products are primarily aimed at life sciences researchers, facilitating the safe and efficient storage of biological materials at low temperatures.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Berkeley, California, specializing in the development of cell therapies for serious autoimmune diseases. Founded in 2018, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, addressing the root causes of inflammatory diseases. The company is advancing its therapeutic platform with product candidates such as KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version utilizing the same chimeric antigen receptor. Through these innovative approaches, Kyverna aims to provide effective treatments and potential cures for patients suffering from autoimmune conditions.
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.
Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.
HC Scientific Technology Co., Ltd. is a company based in Chengdu, China, that specializes in the development, manufacturing, and distribution of genetic testing instruments, reagents, and software. Founded in 2015, the company serves various sectors, including clinical molecular diagnostics, health genetic testing, and agricultural molecular breeding, both domestically and internationally. HC Scientific's product lineup features instruments such as the Matrix Arrayer for reaction plate preparation, the Matrix Cycler for thermal cycling, and the Matrix Scanner for fluorescence detection. Additionally, the company provides consumables like the Matrix plate and Matrix Mix genotyping reagents, along with a data management system known as Matrix Master. Committed to innovation, HC Scientific focuses on autonomous research and development of its intellectual property, aiming to deliver high-throughput, automated, and cost-effective genetic testing solutions.
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.
Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
Abogen Biosciences
Series B in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.
ABclonal Inc. provides biological research agents and services. Its products include next generation sequencing lib preparation kits, molecular biology products, catalog antibody products, catalog proteins, ELISA kits, and western blot tools and reagents. The company also offers peptide, antibody, and protein services. It provides its products through distributors in Europe, Asia, North America, and Oceania. The company was incorporated in 2016 and is based in Woburn, Massachusetts.
Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.
Cleveland Diagnostics, Inc. is a company focused on developing and commercializing innovative cancer diagnostics and screening tests. Founded in 2013 and headquartered in Cleveland, Ohio, the company offers a range of non-invasive blood-based tests designed to screen for various types of cancer, including prostate, breast, and ovarian cancer. Cleveland Diagnostics aims to create a new class of diagnostic tests that demonstrate high sensitivity and specificity, enabling early detection of cancer when it is most treatable. The company has formed a strategic collaboration with Genomic Health to further enhance its diagnostic capabilities.
Exegenesis Bio
Series B in 2021
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.
Shanghai Shenqi Medical Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive vascular interventional products. Established in 2014 and based in Shanghai, the company provides a diverse range of medical devices including releasable embolization systems, peripheral microcatheters, distal access guide catheters, drug-coated coronary balloon catheters, and left atrial appendage occluder systems. These products are designed for various medical applications, including cardiovascular intervention, peripheral vascular intervention, neurovascular intervention, and the treatment of structural heart diseases. Shenqi Medical is committed to delivering innovative solutions for the healthcare industry in China.
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.
Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial orthopedic implants and systems. The company is dedicated to research and development in orthopedics, producing a range of products including artificial hip joints, artificial knee joints, internal fixation devices, and orthopedic surgical instruments. By focusing on advanced technology, Just Medical aims to enhance the quality of orthopedic treatment and improve surgical efficiency for healthcare providers and their patients.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.
Aohua Endoscopy Co., Ltd. is a manufacturer of endoscopy equipment and consumables, offering a range of products including imaging processors, endoscopes, and various accessories. The company specializes in solutions for gastroenterology, respiratory care, ear, nose, and throat (E.N.T) applications, as well as veterinary endoscopy. Founded in 1994, Aohua is headquartered in Shanghai, China, and aims to lead in the innovation of endoscope technology while advancing the field of endoscopic diagnosis and treatment.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.
The company was founded in 2003 and is headquartered in San Diego, California.
Laviana Pharma Co., Ltd. founded in 2005 is a high-tech enterprise. It specializes in providing process and manufacture outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products. It also provides CMC services for IND and NDA submission of innovative developmental drug. It has three wholly-owned subsidiary, namely, Beijing laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in United States.
Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.
Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.